在化疗诱导的血小板缺血症中,给avatrombopag第二次机会
Hanny Al-Samkari1,2, Donald C Moore3
1Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
British journal of haematology
|November 4, 2024
概括
阿瓦特罗姆波帕格在化疗诱导的血小板缺血症 (CIT) 中表现有前途,这是一个常见的癌症并发症. 患者选择和区分从持久性CIT的nadir是癌症患者有效的阿瓦特罗姆波巴格治疗的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗诱导的血小板缺血 (CIT) 是癌症治疗的常见严重并发症.
- 目前,全球范围内没有普遍批准的CIT治疗方法.
- 之前对CIT的阿瓦特罗姆巴格试验没有达到主要终点.
研究的目的:
- 重新评估AVATROMBOPAG在治疗化疗诱导的血小板缺血症 (CIT) 的潜力.
- 强调区分最低点和持久性CIT的重要性.
- 突出患者选择在CIT治疗中具有关键作用的关键作用.
主要方法:
- 审查Galamaga及其同事对CIT的avatrombopag的一系列案例.
- 对患者数据的分析,重点是值与持续性血小板衰竭.
- 考虑影响治疗反应的患者特征.
主要成果:
- 评论表明,在特定的CIT患者亚组中,阿瓦特罗姆波巴可能是有效的.
- 区分纳迪尔和持久性血小板缺血是治疗成功的关键.
- 仔细的患者选择可能会改善CIT中avatrombopag的结果.
结论:
- 阿瓦特罗姆波帕格 (Avatrombopag) 需要进一步调查化疗诱导的血小板缺血症 (CIT).
- 未来的临床试验应侧重于精确的患者分层.
- 了解CIT动态 (nadir与持久) 对于治疗开发至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
175
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
175
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
227
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
227
Anticoagulant Drugs: Low-Molecular-Weight Heparins
624
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
624
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
477
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
477


